• Skip to primary navigation
  • Skip to main content
  • Skip to footer
MotherToBaby

MotherToBaby

Medications and More during pregnancy and breastfeeding

Buscar

Ocultar búsqueda
Shopping Cart
Mostrar búsquedaBuscar
866.626.6847
  • Acerca de
    • Nuestro Trabajo
    • Nuestro Equipo
    • Nuestros Colaboradores
    • Nuestro Impacto
  • Exposiciones
    • Exposiciones Durante el Embarazo y la Lactancia
    • Hojas Informativas
    • Baby Blogs
    • Podcasts
    • Herramienta interactiva
    • Otras Herramientas Educativas
    • App LactRx
  • Estudios
    • Estudios en Curso
    • ¿Qué Está Involucrado?
    • Unirse Ahora
    • Refiere a un Paciente
    • Profesionales de Salud
    • Industria Farmacéutica
    • Publicaciones
  • Profesionales de Salud
    • Educación para Pacientes y Recursos para Proveedores
    • Refiere un Paciente
    • Ordena Materiales
    • Reuniones
  • Medios de Comunicación
    • Solicitudes por los Medios
    • Comunicados de Prensa
    • Inscribirse para Boletín Electrónico
  • En Su Área
  • OTIS
    • Acerca de OTIS
    • Membresía de OTIS
    • Reunión Anual
  • Donar
  • Contactar
  • Mostrar búsquedaBuscar

Naproxen

enero 1, 2024

Selected References:

  • Alano MA, et al. 2001. Analysis of nonsteroidal anti-inflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics, 107:519-523.
  • Center for Drug Evaluation and Research. (n.d.). NSAIDs may cause rare kidney problems in unborn babies. Retrieved October 16, 2020, from https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic
  • Choi EY, et al. 2023. Neonatal and maternal adverse outcomes and exposure to nonsteroidal anti-inflammatory
  • drugs during early pregnancy in South Korea: A nationwide cohort study, PLoS Med 20(2):1-19.
  • Delker E, et al. 2023. Associations of prenatal exposure to non-steroidal anti-inflammatory drugs with preterm birth and small for gestational age infants among women with autoimmune disorders, Pharmacoepidemiol Drug Saf, 32:225–237.
  • Ericson A & Kallen BA. 2001. Nonsteroidal anti-inflammatory drugs in early pregnancy. Reproductive Toxicology, 15:371-375.
  • Esposito DB, et al. 2021. Periconceptional nonsteroidal anti-inflammatory drug use, folic acid intake, and the risk of spina bifida. Birth Defects Res, 113(17):1257-1266.
  • Hernandez RK, et al. 2012. Nonsteroidal antiinflammatory drug use among women and the risk of birth defects. Am J Obstet Gynecol, 206(3):228.e1-8.
  • Hultzsch S, et al. 2021. First trimester naproxen exposure and outcome of pregnancy – a German case series. Reprod Toxicol, 103:51-57.
  • Ito S, et al. 1993. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol; 168(5):1393-1399.
  • Janssen NM & Genta MS. 2000. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med, 160(5):610-619.
  • Kabir Chowdhury MA, et al. 2023. Relationship of nonsteroidal anti-inflammatory drug use during pregnancy with autism spectrum disorder and intellectual disability among offspring. Journal of Women’s Health 32(3):356-365.
  • Kallen BA. 2003. Maternal drug use and infant cleft lip/palate with special reference to corticoids. Cleft Palate Craniofac J, 40(6):624-628.
  • Kallen BA & Olausson PO. 2003. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 17(3):255-261.
  • Koren G et al. 2006. Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. The Annals of Pharmacotherapy, 40:824-829.
  • Malm H & Borish C. 2015. Non-steroidal anti-inflammatory drugs and antirheumatic drugs. In C Schaefer, P Peters, R Miller (Eds.), Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 3rd P. 41-45. London: Elsevier.
  • Markovic M, et al. 2019. Prenatal exposure to non-steroidal anti-inflammatory drugs (NSAIDs) and neurodevelopmental outcomes in children. Pharmacoepidemiology and Drug Safety, 28(4):452-459.
  • McInerney KA, et al. 2017. Preconception use of pain-relievers and time-to-pregnancy: a prospective cohort study. Hum Reprod, 32(1):103-111.
  • Nakhai-Pour HR, et al. 2011. Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. CMAJ, 183(15):1713-1720.
  • Nielsen GL, et al. 2001. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti inflammatory drugs: population based observational study and case control study. BMJ, 322(7281):266-270.
  • Li D, et al. 2003. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ, 327:1-5.
  • Li DK, et al. 2018. Use of non-steroidal anti-inflammatory drugs during pregnancy and the risk of miscarriage. Am J Obstet Gynecol, 219(3):275.e1-275.e8.
  • Ofori B, et al. 2006. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: a nested case-control study. Birth Defects Res B Dev Reprod Toxicol, 77(4):268-279.
  • Ostensen M & Ostensen H. 1996. Safety of nonsteroidal antiinflammatory drugs in pregnant patients with rheumatic disease. J Rheumatol, 23(6):1045-1049.
  • Spencer JP, et al. 2001. Medications in the breast-feeding mother. Am Fam Physician, 64(1):119-127.
  • Tanaka S, et al. 2016. Prediction of fetal ductus arteriosus constriction by systemic and local dermatological formulations of NSAIDs based on PK/PD analysis. In J Clin Pharmacol Ther, 54(10):782-794.

Footer

               

Enlaces Candentes

  • Página Principal
  • Exposiciones
  • Hojas Informativas
  • Baby Blogs
  • Podcasts
  • Estudios de Embarazo
  • Unirse a un Estudio Ahora
  • Profesionales de Salud
  • Refiere un Paciente
  • Ordena Materiales
  • Comunicados de Prensa
  • Donar
  • Pregúntele a un Experto

Estudios en Curso

  • Espondilitis Anquilosante
  • Estreñimiento
  • Coronavirus (COVID-19)
  • Eccema (Moderado-a-Severo)/Dermatitis Atópica
  • Hidradenitis Supurative
  • Lupus
  • Esclerosis Múltiple
  • Psoriasis
  • Artritis Psoriásica

Contactar

Servicio de Información de Exposición
866.626.6847

Estudios de Embarazo
877.311.8972

Consultas de los Medios
619.368.3259
nchavez@mothertobaby.org

MotherToBaby, un servicio de la Organización de Especialistas en Información de Teratología

Derechos de autor © 2025 la Organización de Especialistas en Información de Teratología

  • Accesibilidad
  • Términos
  • Confidencialidad
  • Mapa del Sitio
^

MotherToBaby cuenta con el apoyo de la Administración de Recursos y Servicios de Salud (HRSA) del Departamento de Salud y Servicios Humanos de los Estados Unidos (HHS) como parte de una adjudicación por un total de $6,000,000 con cero porcentaje financiado con fuentes no gubernamentales. Los contenidos son los del autor/es y no representan necesariamente los puntos de vista oficiales de, ni un respaldo, por HRSA, HHS o el Gobierno de los Estados Unidos.